NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino
Garcia, the company’s EVP and Chief Strategy Officer, will present a
corporate update at the Canaccord Genuity 36th Annual Growth
Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at
the InterContinental in Boston, Massachusetts.
A live webcast of the presentation will be accessible through the
Investor Relations section of the company’s website at www.synergypharma.com.
A replay of the webcast will be available on Synergy’s website for 60
days following the conference.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development and
commercialization of novel gastrointestinal (GI) therapies. The company
has pioneered discovery, research and development efforts around
uroguanylin analogs for the treatment of functional GI disorders and
inflammatory bowel disease. Synergy’s proprietary technology platform is
based on uroguanylin, a naturally occurring human GI peptide, and
includes two lead product candidates – plecanatide and dolcanatide.
Plecanatide is the company’s first uroguanylin analog currently being
evaluated for use as a once-daily tablet for chronic idiopathic
constipation and irritable bowel syndrome with constipation. Dolcanatide
is the company’s second uroguanylin analog currently being explored for
ulcerative colitis. For more information, please visit www.synergypharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005086/en/
Contacts
Synergy Pharmaceuticals Inc.
Gem Hopkins, 212-584-7610
VP,
Investor Relations and Corporate Communications
ghopkins@synergypharma.com
Source: Synergy Pharmaceuticals Inc.
Cet article Synergy Pharmaceuticals to Present at Canaccord Genuity 36th
Annual Growth Conference est apparu en premier sur EEI-BIOTECHFINANCES.